Pharmaceutical giant Eli Lilly shared encouraging clinical trial data with healthcare professionals on Saturday, revealing that its experimental obesity medication retatrutide delivered multiple health benefits beyond weight reduction, including improvements in sleep breathing disorders and joint pain relief.
During a Phase 3 clinical study, researchers discovered that weekly doses of retatrutide decreased the severity of moderate-to-severe obstructive sleep apnea by 60.6% among obese participants. The company’s existing medication Zepbound has already received regulatory approval for treating this sleep disorder.
The same clinical trial demonstrated that the experimental drug lessened knee osteoarthritis discomfort by as much as 73.1%, according to Lilly’s findings. These research outcomes were shared during an American Diabetes Association medical conference taking place in New Orleans.
The pharmaceutical company had earlier revealed results from the two research studies featured on Saturday, which showed obese participants achieved 28% body weight reduction while adults managing type 2 diabetes saw substantial decreases in their blood glucose measurements.
During one research study, 2% of diabetic participants receiving the medication’s smallest dosage experienced serious cardiovascular complications. However, according to comprehensive findings published in the Lancet on Saturday, these medical events weren’t definitively linked to the drug treatment.
Retatrutide represents Lilly’s investigational “triple G” medication, designed to activate GLP-1 pathways, a secondary obesity-controlling hormone known as GIP, and the body’s receptor sites for a third hormone called glucagon.
The Indiana-headquartered pharmaceutical firm is competing alongside competitors such as Denmark’s Novo Nordisk to capture the rapidly expanding marketplace for obesity and diabetes treatments.
